PTC Therapeutics Completes Acquisition of Sangamo's ST-920 (Isaralgagene Civaparvovec) Fabry Disease Gene Therapy; Rolling BLA to Finish in Q4 2026
PTC Therapeutics said on Monday, September 21, 2026 that it completed its acquisition of ST-920 (isaralgagene civaparvovec) from Sangamo Therapeutics. ST-920 is a one-time AAV gene therapy for Fabry disease that is designed to enable long-term production of the missing alpha-galactosidase A enzyme in place of chronic enzyme replacement therapy. Under terms announced in August, PTC won the asset in Sangamo's Chapter 11 auction for $111 million upfront plus up to $100 million in approval milestones; Eli Lilly separately bought Sangamo's zinc finger programs for $50 million. ST-920 holds FDA Orphan Drug, Fast Track, and RMAT designations and EMA PRIME eligibility, and PTC expects to complete a rolling Biologics License Application for accelerated approval in the fourth quarter of 2026.